Table 1.
Full results of the case study screen organized by reporter and monoclonal antibody.
| Reporter | Monoclonal Antibody | Cutaneous Adverse Effect |
|---|---|---|
| Rauer et. al. | Daclizumab | DRESS syndrome |
|
| ||
| Daclizumab | DRESS syndrome | |
|
| ||
| Naidoo et. al. | Nivolumab | Drug-induced hypersensitivity dermatitis |
|
| ||
| Ipilimumab/Nivolumab | Maculopapular rash, vesicles, erosions | |
|
| ||
| Ipilimumab/Durvalumab | Lichenoid dermatitis, blisters, exanthema | |
|
| ||
| Fontecilla et. al. | Durvalumab/Tremelimumab | Epidermal necrolysis, eosinophilic infiltrate |
|
| ||
| Oiwa et. al. | Ixekizumab | Psoriasiform eruptions |
|
| ||
| Anthony et. al. | Ixekizumab | Pruritic, photosensitive plaques |
|
| ||
| Maria et. al. | Ixekizumab | Lentiginous eruption |
|
| ||
| Hayashida et. al. | Secukinumab | Pemphigus vulgaris |
|
| ||
| Thompson et. al. | Secukinumab | Ulcerative lichenoid mucositis |
|
| ||
| Al Hammadi & Parmar | Dupilumab | Erythema, pruritus and diffuse skin peeling |
|
| ||
| Takahashi et. al. | Brodalumab | Palmar pustular eruption |